| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
|
N Engl J Med
|
2004
|
25.68
|
|
2
|
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
|
J Clin Oncol
|
2005
|
6.00
|
|
3
|
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
|
Lancet Oncol
|
2009
|
5.57
|
|
4
|
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
|
J Clin Oncol
|
2012
|
5.41
|
|
5
|
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
|
Lancet Oncol
|
2012
|
3.36
|
|
6
|
Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial.
|
J Clin Oncol
|
2014
|
2.51
|
|
7
|
Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment center, treatment schedule, and gender and is prognostic parameter for local control: results of study CAO/ARO/AIO-94.
|
Int J Radiat Oncol Biol Phys
|
2006
|
2.26
|
|
8
|
Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy.
|
J Clin Oncol
|
2005
|
2.07
|
|
9
|
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
|
Lancet Oncol
|
2015
|
1.97
|
|
10
|
Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results.
|
J Clin Oncol
|
2005
|
1.83
|
|
11
|
Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.58
|
|
12
|
Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
|
J Clin Oncol
|
2006
|
1.57
|
|
13
|
Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas.
|
Cancer Res
|
2007
|
1.53
|
|
14
|
Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer.
|
J Clin Oncol
|
2007
|
1.43
|
|
15
|
Aneuploidy-dependent massive deregulation of the cellular transcriptome and apparent divergence of the Wnt/beta-catenin signaling pathway in human rectal carcinomas.
|
Cancer Res
|
2006
|
1.31
|
|
16
|
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
|
Ann Oncol
|
2014
|
1.07
|
|
17
|
Molecular cytogenetics: genomic imbalances in colorectal cancer and their clinical impact.
|
Cell Oncol
|
2006
|
1.07
|
|
18
|
Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group.
|
Ann Surg Oncol
|
2007
|
1.02
|
|
19
|
Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy.
|
World J Gastroenterol
|
2008
|
1.02
|
|
20
|
Targeting NCA-95 and other granulocyte antigens and receptors with radiolabeled monoclonal antibodies (Mabs).
|
Q J Nucl Med Mol Imaging
|
2010
|
1.01
|
|
21
|
Survivin as a prognostic/predictive marker and molecular target in cancer therapy.
|
Curr Med Chem
|
2012
|
1.00
|
|
22
|
Frequency of HER-2 positivity in rectal cancer and prognosis.
|
Am J Surg Pathol
|
2013
|
1.00
|
|
23
|
Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy.
|
Am J Surg Pathol
|
2005
|
0.97
|
|
24
|
Optimal lymph node harvest in rectal cancer (UICC stages II and III) after preoperative 5-FU-based radiochemotherapy. Acetone compression is a new and highly efficient method.
|
Am J Surg Pathol
|
2012
|
0.96
|
|
25
|
Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.95
|
|
26
|
Differences between clinical trial participants and patients in a population-based registry: the German Rectal Cancer Study vs. the Rostock Cancer Registry.
|
Dis Colon Rectum
|
2009
|
0.95
|
|
27
|
Preoperative chemoradiotherapy does not necessarily reduce lymph node retrieval in rectal cancer specimens--results from a prospective evaluation with extensive pathological work-up.
|
J Gastrointest Surg
|
2009
|
0.93
|
|
28
|
High-grade acute organ toxicity during preoperative radiochemotherapy as positive predictor for complete histopathologic tumor regression in multimodal treatment of locally advanced rectal cancer.
|
Strahlenther Onkol
|
2009
|
0.92
|
|
29
|
The role of survivin for radiation oncology: moving beyond apoptosis inhibition.
|
Curr Med Chem
|
2011
|
0.91
|
|
30
|
Failure of downregulation of survivin following neoadjuvant radiochemotherapy in rectal cancer is associated with distant metastases and shortened survival.
|
Clin Cancer Res
|
2010
|
0.90
|
|
31
|
Discrepancies between medical oncologists and surgeons in assessment of resectability and indication for chemotherapy in patients with colorectal liver metastases.
|
Br J Surg
|
2014
|
0.89
|
|
32
|
Rectal cancer: state of the art in 2012.
|
Curr Opin Oncol
|
2012
|
0.89
|
|
33
|
Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation.
|
Cancer Lett
|
2008
|
0.88
|
|
34
|
Comparison of chromosomal aberrations in primary colorectal carcinomas to their pulmonary metastases.
|
Cancer Genet
|
2011
|
0.87
|
|
35
|
Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
|
J Pathol
|
2004
|
0.86
|
|
36
|
Chromosomal copy number changes of locally advanced rectal cancers treated with preoperative chemoradiotherapy.
|
Cancer Genet Cytogenet
|
2009
|
0.86
|
|
37
|
Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.
|
Cancer
|
2012
|
0.86
|
|
38
|
Lymph node metastases in rectal cancer after preoperative radiochemotherapy: impact of intramesorectal distribution and residual micrometastatic involvement.
|
Am J Surg Pathol
|
2013
|
0.85
|
|
39
|
Oxaliplatin-Induced Leukocytoclastic Vasculitis under Adjuvant Chemotherapy for Colorectal Cancer: Two Cases of a Rare Adverse Event.
|
Case Rep Oncol
|
2013
|
0.85
|
|
40
|
Distinct chromosomal profiles in metastasizing and non-metastasizing colorectal carcinomas.
|
Cell Oncol
|
2006
|
0.85
|
|
41
|
Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study.
|
Int J Radiat Oncol Biol Phys
|
2013
|
0.83
|
|
42
|
Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.
|
Am J Surg Pathol
|
2006
|
0.83
|
|
43
|
Gender-specific acute organ toxicity during intensified preoperative radiochemotherapy for rectal cancer.
|
Oncologist
|
2011
|
0.82
|
|
44
|
Novel Carcinoembryonic-Antigen-(CEA)-Specific Pretargeting System to Assess Tumor Cell Viability after Irradiation of Colorectal Cancer Cells.
|
Strahlenther Onkol
|
2011
|
0.82
|
|
45
|
[Individualizing treatment for locally advanced rectal cancer].
|
Chirurg
|
2009
|
0.81
|
|
46
|
Gender affects acute organ toxicity during radiochemotherapy for rectal cancer: long-term results of the German CAO/ARO/AIO-94 phase III trial.
|
Radiother Oncol
|
2013
|
0.81
|
|
47
|
Preoperative chemoradiotherapy in locally advanced rectal cancer: correlation of a gene expression-based response signature with recurrence.
|
Cancer Genet Cytogenet
|
2009
|
0.81
|
|
48
|
Induction chemotherapy before chemoradiotherapy and surgery for locally advanced rectal cancer : is it time for a randomized phase III trial?
|
Strahlenther Onkol
|
2010
|
0.81
|
|
49
|
Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification?
|
World J Surg Oncol
|
2010
|
0.80
|
|
50
|
High chromosomal instability in brain metastases of colorectal carcinoma.
|
Cancer Genet Cytogenet
|
2010
|
0.80
|
|
51
|
[Rectal cancer: current status of multimodal therapy--when and how?].
|
Zentralbl Chir
|
2011
|
0.80
|
|
52
|
Downstage migration after neoadjuvant chemoradiotherapy for rectal cancer: the reverse of the Will Rogers phenomenon?
|
Cancer
|
2015
|
0.79
|
|
53
|
STED super-resolution microscopy of clinical paraffin-embedded human rectal cancer tissue.
|
PLoS One
|
2014
|
0.78
|
|
54
|
EGFR and β1-integrin targeting differentially affect colorectal carcinoma cell radiosensitivity and invasion.
|
Radiother Oncol
|
2015
|
0.78
|
|
55
|
HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer.
|
Oncotarget
|
2015
|
0.77
|
|
56
|
β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases.
|
Clin Exp Metastasis
|
2016
|
0.77
|
|
57
|
Stage-Dependent Frequency of Lymph Node Metastases in Patients With Rectal Carcinoma After Preoperative Chemoradiation: Results from the CAO/ARO/AIO-94 Trial and From a Comparative Prospective Evaluation With Extensive Pathological Workup.
|
Dis Colon Rectum
|
2016
|
0.77
|
|
58
|
A special device (double-hole belly board) and optimal radiation technique to reduce testicular radiation exposure in radiotherapy of rectal cancer.
|
Radiother Oncol
|
2007
|
0.76
|
|
59
|
Comprehensive lymph node morphometry in rectal cancer using acetone compression.
|
J Clin Pathol
|
2015
|
0.75
|
|
60
|
Comment on "lymph nodes after preoperative chemoradiotherapy for rectal carcinoma: number, status, and impact on survival".
|
Am J Surg Pathol
|
2009
|
0.75
|
|
61
|
Neoadjuvant Therapy in Rectal Cancer - Biobanking of Preoperative Tumor Biopsies.
|
Sci Rep
|
2016
|
0.75
|
|
62
|
Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long-term efficacy results of a prospective phase 2 study.
|
Cancer
|
2016
|
0.75
|